Extracellular Vesicles Carrying Tenascin‑C are Clinical Biomarkers and Improve Tumor-Derived DNA Analysis in Glioblastoma Patients

• Published in: ACS nano Vol. 19; no. 10; pp. 9844 - 9859
• Main Authors: Salviano-Silva, Amanda, Wollmann, Kathrin, Brenna, Santra, Reimer, Rudolph, Neumann, Julia E., Dottermusch, Matthias, Woythe, Laura, Maire, Cecile L., Puig, Berta, Schüller, Ulrich, Saul, Meike J., Westphal, Manfred, Drexler, Richard, Dührsen, Lasse, Gempt, Jens, Heiland, Dieter H., Lamszus, Katrin, Ricklefs, Franz L.
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 18.03.2025
• Subjects: Adult; Aged; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Brain Neoplasms - blood; Brain Neoplasms - diagnosis; Brain Neoplasms - genetics; DNA, Neoplasm - genetics; Extracellular Vesicles - chemistry; Extracellular Vesicles - metabolism; Female; Glioblastoma - blood; Glioblastoma - diagnosis; Glioblastoma - genetics; Glioblastoma - metabolism; Glioblastoma - pathology; Humans; Male; Middle Aged; Tenascin - blood; Tenascin - genetics; Tenascin - metabolism; extracellular vesicles; glioblastoma; biomarkers; liquid biopsy; Tenascin-C
• ISSN: 1936-0851; 1936-086X; 1936-086X
• DOI: 10.1021/acsnano.4c13599

Extracellular vesicles (EVs) act as carriers of biological information from tumors to the bloodstream, enabling the detection of circulating tumor material and tracking of disease progression. This is particularly crucial in glioblastoma, a highly aggressive and heterogeneous tumor that is challenging to monitor. Using imaging flow cytometry (IFCM), we conducted an immunophenotyping analysis of eight glioma-associated antigens and tetraspanins in plasma EVs from 37 newly diagnosed glioblastoma patients (pre- and post-surgery), 11 matched individuals with recurrent glioblastoma, and 22 healthy donors (HD). Tenascin-C (TNC) positive EVs displayed the strongest differences in newly diagnosed and recurrent glioblastoma patients, when compared to non-tumor subjects. Among dual-positive subpopulations, TNC+/CD9+ EVs were the most elevated in newly diagnosed (FC = 7.6, p <0.0001, AUC = 81%) and recurrent patients (FC = 16.5, p <0.0001; AUC = 90%) than HD. In comparison with other CNS tumors (n = 25), this subpopulation was also 34.5-fold higher in glioblastoma than in meningioma cases (p <0.01). Additionally, TNC+/CD9+ EV levels were 3.3-fold elevated in cerebrospinal fluid from glioblastoma patients (n = 6) than controls (p <0.05). Aberrant TNC levels were further observed in glioblastoma EVs from different sources and purified via different methods. Immunohistochemical analysis revealed high levels of TNC in tumor tissues. Spatial transcriptomic analysis indicated a TNC overexpression in malignant cell populations of glioblastoma resections, particularly in cells with mesenchymal-like signatures and chromosomal aberrations. Lastly, we purified TNC+ EVs from plasma of 21 glioblastoma patients by magnetic sorting and detected the oncogenic mutation TERT*C228T by droplet digital PCR. The mutant allele frequency was higher in TNC+ EVs vs TNC-negative EVs (FC = 32, p <0.001), total EVs (FC = 5.3, p <0.001) or cell-free DNA (FC = 5.3, p <0.01). In conclusion, circulating TNC+ EVs may have potential as clinical biomarkers in glioblastoma, and their purification could improve the identification of tumor-specific mutations in liquid biopsies.